ped/pea-15 is a cytosolic protein performing a broad antiapoptotic function. We show that, upon DMBA/TPAinduced skin carcinogenesis, transgenic mice overexpressing ped/pea-15 (Tg ped/pea-15 ) display early development of papillomas and a four-fold increase in papilloma number compared to the nontransgenic littermates (Po0.001). The malignant conversion frequency was 24% for the Tg ped/pea-15 mice and only 5% in controls (Po0.01). The isolated application of TPA, but not that of DMBA, was sufficient to reversibly upregulate ped/pea-15 in both untransformed skin and cultured keratinocytes. ped/pea-15 protein levels were also increased in DMBA/TPAinduced papillomas of both Tg ped/pea-15 and control mice. Isolated TPA applications induced Caspase-3 activation and apoptosis in nontransformed mouse epidermal tissues. The induction of both Caspase-3 and apoptosis by TPA were four-fold inhibited in the skin of the Tg ped/pea-15 compared to the nontransgenic mice, accompanied by a similarly sized reduction in TPA-induced JNK and p38 stimulation and by constitutive induction of cytoplasmic ERK activity in the transgenics. ped/pea-15 expression was stably increased in cell lines from DMBA/TPAinduced skin papillomas and carcinomas, paralleled by protection from TPA apoptosis. In the A5 spindle carcinoma cell line, antisense inhibition of ped/pea-15 expression simultaneously rescued sensitivity to TPAinduced Caspase-3 function and apoptosis. The antisense also reduced A5 cell ability to grow in semisolid media by 65% (Po0.001) and increased by three-fold tumor latency time (Po0.01). Thus, the expression levels of ped/pea-15 control Caspase-3 function and epidermal cell apoptosis in vivo and determine susceptibility to skin tumor development.
Introduction
There is evidence that deregulation of apoptosis plays an important role in tumorigenesis. Indeed, alterations of apoptosis-related genes have been identified in a number of human cancers (Debatin and Krammer, 2004) . ped/ pea-15 is a 15 kDa, death effector domain (DED)-containing protein featuring ubiquitous expression, and originally identified as a major astrocytic phosphoprotein (Araujo et al., 1993; Condorelli et al., 1998) . ped/ pea-15 exerts a broad antiapoptotic action through at least three distinct mechanisms. Firstly, it inhibits the formation of the death-inducing signaling complex (DISC) and Caspase-3 activation triggered by FASL, tumor necrosis factor alpha, and the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) (Condorelli et al., 1999; Kitsberg et al., 1999; Hao et al., 2001) . Secondly, ped/pea-15 inhibits stress-induced apoptosis by simultaneously blocking stress-activated protein kinases (SAPK) and increasing the function of cytosolic extracellular signal-regulated kinases (ERK1/2) (Condorelli et al., 2002) . Thirdly, ped/ pea-15 prevents degradation of the antiapoptotic protein XIAP caused by release of proapoptotic mitochondrial proteins .
Studies in our own and other laboratories have shown that elevated expression of ped/pea-15 occurs in several tumor-derived cell lines. Indeed, ped/pea-15 is highly expressed in human glioma and metastatic breast cancer cell lines and induces resistance to chemotherapic agents in these cells (Ramos et al., 2000; Hao et al., 2001; Condorelli et al., 2002; Trencia et al., 2004) . ped/pea-15 is also expressed at high levels in tumor cell lines derived from human larynx, cervix, and skin tumors (Condorelli et al., 1998) , and in human mammary carcinomas as well (Tsukamoto et al., 2000) . Finally, the ped/pea-15 gene was demonstrated to be increasingly expressed during tumor progression in murine squamous carcinomas (Dong et al., 2001) . However, despite these mounting evidence supporting the role of ped/pea-15 in neoplastic transformation and tumor progression, whether ped/pea-15 has a direct role in tumorigenesis and progression in vivo has not been investigated yet.
Transgenic mice overexpressing ped/pea-15 ubiquitously have recently been generated (Vigliotta et al., 2004) . These mice feature reduced glucose tolerance due to both impaired insulin action and secretion. We have now used these transgenics and a well-characterized mouse model of chemically induced multistep skin carcinogenesis (Balmain and Harris, 2000) to explore the role of ped/pea-15 in the initiation, promotion and progression of skin tumors. Our study shows, for the first time, that ped/pea-15 expression level has a significant impact on skin tumor development in a mouse model of chemically induced skin carcinogenesis.
Results

Skin carcinogenesis in ped/pea-15 transgenic mice
We have investigated whether the variation in ped/pea-15 expression levels affects skin tumorigenesis. To this end, we have used transgenic mice overexpressing the human cDNA of ped/pea-15 (Tg ped/pea-15 ; Vigliotta et al., 2004) . Based on Western blot analysis, ped/pea-15 protein was overexpressed by about four-fold (Po0.001) in the epidermis of these transgenics, as compared to their nontransgenic littermates (WT) (Figure 1a) .
Tg ped/pea-15 and control mice (n ¼ 40/group; M/F ¼ 1) were subjected to a single DMBA topical application followed by repeated applications of the tumor promoter TPA. This treatment resulted in the development of papillomatous lesions. Visible papillomas began to appear on the dorsal skin of both the Tg ped/pea-15 and WT mice at 7 weeks of promotion, indicating no difference in the benign tumor latency between the two groups of mice (Figure 1b) . The incidence of papilloma development reached 100% at 10 weeks of promotion in the Tg ped/pea-15 , and at week 12 in the WT mice (Po0.001; Figure 1b) . Interestingly, there was a significant increase in the average number of papillomas per mouse in the Tg ped/pea-15 compared to WT mice throughout the entire promoter treatment period. The difference in papilloma number was already significant at week 8. By the end of promotion (week 15), Tg ped/pea-15 mice showed 18.4710.7 papillomas per mouse compared to 4.974.8 in the WT mice (Po0.001) (Figure 1c) . No gender-related difference was evidenced in either the incidence or the number of papillomas in transgenic and control mice (data not shown).
At 35 weeks after promoter treatment suspension, the lesions from Tg ped/pea-15 and WT mice were subjected to histological examination. The malignant conversion frequency was 24% in the Tg ped/pea-15 mice (12 out of 50 analysed lesions, Figure 2A ). As in previous studies (Burns et al., 1978) , the frequency was only 5% (two out of 40 analysed lesions) in the control mice (Po0.001), however. Sections of the lesions from Tg ped/pea-15 mice more frequently showed the presence of a poorly differentiated epithelial neoplasm composed of nests of small undifferentiated cells with minimal keratinization, occasional squamous pearl formation and extremely Figure 2B(c) ). As shown in Figure 2B (d), the majority of the neoplastic cells displayed intense PCNA nuclear labeling, and stained cells were scattered throughout the tissue, reflecting the neoplastic modifications. At variance, lesions from WT mice more commonly showed benign hyperplastic proliferation of the epidermis, with epithelial cells featuring normal morphological characteristics, without significant nuclear atypia ( Figure 2B(a) ). Based on PCNA immunostaining, cycling cells were present only at the basal epidermal level ( Figure 2B(b) ). Differentiating squamous cells exhibited no staining, consistent with lack of dysplatic/neoplastic changes in the WT mouse skin.
ped/pea-15 levels during skin tumor initiation and promotion
To investigate the significance of ped/pea-15 expression to skin tumor development and malignant progression, we have first analysed ped/pea-15 levels in papillomatous lesions and in the corresponding skin upon regression of the lesions. Despite the four-fold increase in the normal skin of Tg ped/pea-15 versus control mice, ped/pea-15 was raised to comparable absolute levels in papillomas from WT and Tg ped/pea-15 mice (Figure 3a ). Immunohistochemical analysis with ped/pea-15 antibodies revealed comparable distribution of ped/pea-15 between the stromal and epithelial components of the epidermal tissues from transgenic and control mice (data not shown). After papilloma regression, there were no longer differences in ped/pea-15 levels between the skin Figure 3 ped/pea-15 expression in cell lines from chemically induced skin tumors and papillomas from Tg ped/pea-15 mice. (a) Papillomatous lesions (P; n ¼ 32), samples from unaffected skin of the surrounding areas (NS; n ¼ 34), or from the skin corresponding to the papillomatous base upon regression of the lesion (R; n ¼ 28) from control (WT) and ped/pea-15 transgenic mice (Tg ped/pea-15 ) animals (n ¼ 27/group) were excised and lysed as described in the legend to Figure 1 . ped/pea-15 and tubulin expression were detected in the lysates (50 mg of proteins/sample) by Western blotting and autoradiography. Blots were revealed by ECL and autoradiography and analysed by laser densitometry. Bars represent the average (values7s.d.) of the tubulin-normalized expression of ped/pea-15 in duplicate determinations from four independent experiments. The difference between P and NS was significant at the P ¼ 0.001 (Wt) and Po0.001 (Tg). (b) The C5N, P1 and A5 cell lines derived, respectively, from normal keratinocytes, DMBA/TPA-induced papillomas and spindle cell carcinomas, were cultured as described under Materials and methods. Cell proteins (50 mg) were Western blotted with ped/pea-15 or tubulin antibodies as indicated. Blots were revealed and further analysed as in (a). Bars represent the average (values7s.d.) of the tubulin-normalized expression of ped/ pea-15 in duplicate determinations from four independent experiments. The difference between the P1 and C5N cells and between the A5 and C5N cells were significant at the Po0.001 level. A representative autoradiograph is also shown ped/pea-15 transgenic mice and skin cancer P Formisano et al where the lesion had originated and the surrounding normal skin, in both the Tg ped/pea-15 and the WT mice.
We next analysed mouse cell lines derived from DMBA/TPA-induced skin tumors at different stages of carcinogenesis (Portella et al., 1998) . By Western blotting, ped/pea-15 protein was similarly overexpressed (almost three-fold; Po0.001) in both the P1 benign papilloma cells and the A5 highly anaplastic, invasive spindle carcinoma cells compared to the C5N immortalized nontumorigenic keratinocytes (Figure 3b ). Thus, in the cell lines as well as in vivo, the increase in ped/pea-15 protein level appeared to occur at an early stage during skin carcinogenesis.
Repeated applications of the DMBA initiator on the mouse skin did not change ped/pea-15 levels either in the Tg ped/pea-15 or in WT mice (Figure 4a ). Also, transfection of the constitutively active H-Ras61 mutant in keratinocytes showed no effect on ped/pea-15 levels ( Figure 4b ), indicating that Ras activation is not sufficient to upregulate ped/pea-15. At variance with DMBA, TPA treatment raised ped/pea-15 expression in skin cells, both in the absence and in the presence of the H-Ras61 mutant ( Figure 4b ). Indeed, exposure of the nontumorigenic C5N keratinocytes to 100 mg/ml TPA increased ped/pea-15 protein level in a time-dependent manner ( Figure 5a ). The effect achieved a plateau (fivefold increase) within 24 h and was maintained for 24 more hours, returning to baseline upon TPA withdrawal. Also, a single TPA application to the skin of both WT and Tg ped/pea-15 mice caused a five-fold elevation of ped/pea-15 protein for up to 48 h, declining thereafter and returning to the pretreatment level by 144 h (still four-fold higher in transgenic compared to WT mice; Figure 5b ). Previous studies showed that phosphorylation by both Akt/PKB and PKC increases intracellular stability of ped/pea-15 (Trencia et al., 2003) . Based on immunoblotting with specific pSer116 and pSer104 ped/pea-15 antibodies, these increased ped/ pea-15 levels in TPA-treated skin were accompanied by 2.5-and four-fold increased phosphorylation of ped/ pea-15 on the Akt/PKB and PKC sites (Ser116 and Ser104, respectively). There were no differences in these phosphorylations in Wt and transgenic mice suggesting that increased ped/pea-15 stability may, at least in part, account for the effect of TPA in these animals ( Figure 5c ).
Effect of ped/pea-15 on skin tissue apoptosis
To examine the consequences of ped/pea-15 overexpression and its role in skin tumorigenesis, we compared in vivo apoptosis in the skin of Tg ped/pea-15 and WT mice upon the application of TPA. Based on skin lysate determination, Tg ped/pea-15 mice showed a significant decrease in the number of apoptotic cells compared to WT animals ( Figure 6a ). Importantly, TPA application to the skin of WT mice induced the appearance of the 20K fragment of the terminal caspase Caspase-3 in the lysates, evidencing Caspase-3 activation (Figure 6b) . Activation of Caspase-3 by TPA was barely detectable in the skin of Tg ped/pea-15 mice, however. Consistently, cleavage of the Caspase-3 substrate PARP was well evident upon treating WT mouse skin with TPA, but >10-fold less measurable in Tg ped/pea-15 mice (Figure 6c ).
At variance with Caspase-3, TPA treatment exhibited very little effect on the activation of the upstream caspase, Caspase-8, in both WT and Tg ped/pea-15 mouse skin (data not shown).
In different cell types, ped/pea-15 protects the inhibitor of apoptosis XIAP from the intracellular degradation following certain apoptotic stimuli, thereby preventing Caspase-3 activation . However, skin lysates from WT and Tg ped/pea-15 mouse showed no difference in XIAP levels (Figure 7a ), suggesting that alternative mechanisms are responsible for the reduced apoptosis occurring in the Tg ped/pea-15 mouse skin after TPA exposure. Indeed, previous studies in 293 cells indicated that ped/pea-15 antiapoptotic function requires ped/pea-15 simultaneous inhibition of the SAPK signaling system of JNK/p38 and activation of ERK1/2 (Condorelli et al., 2002) . In WT mouse skin, TPA elicited a 10-fold increase in phosphorylation of the key activation sites of JNK (Thr183 and Tyr185) and those of p38 (Thr180, Thr182), indicating activation of these kinases (Figure 7b) . Interestingly, the effect of TPA was five-fold reduced in Tg ped/pea-15 mouse skin, despite normal expression of both JNK and p38. ERK1/2 phosphorylation was also constitutively increased in Tg ped/pea-15 compared to Wt mouse skin (Figure 7c ). Despite the eight-fold induction in the WT mouse, ERK phosphorylation in response to TPA showed little further increase in the transgenics, with no significant difference in ERK1/2 expression. Consistent with the reported ability of ped/pea-15 to prevent nuclear migration of ERK1/2, phosphorylation of the ELK substrate in response to TPA was drastically reduced in tissues from Tg ped/pea-15 compared to control mice. At variance with ELK, TPA phosphorylation of the H3 histone target of the ERK1/2-downstream and ped/pea-15 binding kinase RSK2 (Vaidayanathan and Ramos, 2003) showed no difference in Tg ped/pea-15 and control mice (data not shown). Thus, at least in part, overexpression of ped/pea-15 may inhibit TPA-induced apoptosis by dysregulating selective pathways of the MAPK signaling and by inhibiting Caspase-3.
The role of caspase-3 inhibition in chemically induced skin tumorigenesis
To further address the involvement of impaired Caspase-3 activation in the increased susceptibility to skin carcinogenesis of the Tg ped/pea-15 mice, we first compared TPA effect in the C5N nontumorigenic mouse keratinocytes and the A5 highly malignant invasive spindle carcinoma cells. Based on its own cleavage and that of the PARP substrate, TPA induction of Caspase-3 was barely detectable in the ped/pea-15 overexpressing A5 cells, despite the evident effect occurring in the C5N keratinocytes (Figure 8a ). The reduced activation of Caspase-3 in the A5 carcinoma cells was paralleled by a six-fold decrease in TPA-induced apoptosis, compared to the C5N keratinocytes ( Figure 8b ). We then silenced the expression of ped/pea-15 using a specific antisense cDNA (Hao et al., 2001 ). In the A5 cells, the antisense inhibited ped/pea-15 expression to levels comparable to those of the untreated C5N keratinocytes (Figure 8c ). In parallel, the antisense rescued TPA apoptosis in the A5 cells, rendering the A5 as responsive to TPA as the C5N cells (Figure 8b ). Caspase-3 and PARP cleavage in response to TPA was similarly rescued in antisensetransfected A5 cells (Figure 8a ). The colony growth rate in semisolid medium was also reduced in the antisense expressing A5 clones compared to cells tansfected with the empty vector (65% reduction; Po0.001) (Table 1) . Importantly, injection of A5 cells transfected with either the ped/pea-15 antisense cDNA or the empty vector into athymic mice showed no significant difference in tumor incidence. However, the tumor latency period of the antisense expressing clones was almost three-fold increased compared to that of control cells (Po0.01).
Discussion
There is evidence that increased expression of the antiapoptotic protein ped/pea-15 is associated to development of malignancy (Condorelli et al., 1998; Ramos et al., 2000; Tsukamoto et al., 2000; Dong et al., 2001; Hao et al., 2001) . However, no information is available, to date, to assess whether modulation of ped/pea-15 expression may directly affect tumorigenesis and/or progression in vivo. Chemically induced skin carcinogenesis studies have provided valuable information concerning the impact of genetic alterations on multistep tumorigenesis and progression in genetically modified mice (Balmain and Harris, 2000) . In the present paper, we have addressed the role of ped/pea-15 in skin tumor initiation, promotion and progression and used transgenic mice overexpressing the ped/pea-15 gene. These mice express three-to four-fold higher skin levels of ped/pea-15 compared to their nontransgenic littermates. We now report that, in parallel with the increased ped/pea-15 expression, the transgenics show Effects of TPA on XIAP expression and JNK, p38, ERK1/2 and ELK1 phosphorylations. Transgenic and control mice (n ¼ 12/group; M/F ratio ¼ 1 in each group) were subjected to TPA applications (6.25 mg of TPA in 200 ml acetone for 24 h) as described under Materials and methods. Samples from the treated skin were excised and analysed by Western blotting with XIAP, tubulin (a), phospho-JNK, JNK, phospho-p38, p38 (b), phospho-ERK1/2, ERK1/2, phospho-Elk1, and Elk-1 antibodies (c). Blots were revealed by ECL and autoradiography. The autoradiographs shown are representative of four (a and b) and three (c) independent experiments ped/pea-15 transgenic mice and skin cancer P Formisano et al anticipated as well as increased occurrence of benign papillomatous lesions upon being topically treated with the tumor initiator DMBA followed by repeated applications of the tumor promoter TPA. Interestingly, ped/pea-15 expression is also increased in papillomas from WT mice, compared to the adjacent normal skin. The significance of the increased ped/pea-15 levels to skin tumorigenesis is further strengthened by the finding that, upon papilloma regression, ped/pea-15 returns to basal levels in the skin where the lesions have been produced. In addition, the malignant conversion frequency of the papillomatous lesion was significantly higher in ped/pea-15 transgenic compared to the control animals. These results indicate, for the first time, that increased levels of ped/pea-15 confer greater susceptibility to skin carcinogenesis in vivo and may enhance cutaneous tumor progression toward malignancy. Indeed, after suspension of TPA treatment, the transgenic mice maintain stably elevated ped/pea-15 levels compared to the WT animals where the effect of TPA vanishes.
We show that the constitutively active H-Ras61 mutant does not affect ped/pea-15 expression levels in keratinocytes. Consistently, DMBA application did not upregulate ped/pea-15 in mouse skin, indicating that Ras mutation is not sufficient to cause ped/pea-15 overexpression. At variance, treatment with TPA alone rapidly increased ped/pea-15 expression levels in the skin of both transgenic and control mice, suggesting that ped/pea-15 overexpression represents an early event during cutaneous tumor promotion, though not initiation. At least in part, the effect of TPA may be mediated by induction of PKB/Akt and PKC. Indeed, (i) phosphorylation of ped/pea-15 on PKB/Akt and PKC sites is increased in TPA-treated skin; and (ii) previous studies (Trencia et al., 2003) demonstrated that phosphorylation of these sites increases cellular stability of ped/pea-15. In addition, transformed cell lines derived from DMBA/TPA-induced skin tumors consistently show higher ped/pea-15 levels compared to immortalized nontumorigenic keratinocytes. It is conceivable, therefore, that higher ped/pea-15 levels may confer a distinctive advantage to the cells upon DMBA initiation, leading to selection of those overexpressing ped/pea-15.
Transgenic mice overexpressing ped/pea-15 feature insulin-resistance and decreased glucose tolerance (Vigliotta et al., 2004) . Considerable epidemiological evidence exists indicating that these metabolic abnormalities have a role in determining the occurrence of a Colonies larger than 64 cells were scored after 3 weeks. Colonyforming efficiency was calculated by dividing the number of colonies formed by the number of plated cells Â 100. Tumorigenicity was assayed by injecting 1 Â 10 6 cells into 6-week-old athymic mice. ped/pea-15 transgenic mice and skin cancer P Formisano et al number of tumors in humans (Calle and Kaaks, 2004) . Transgenic mice overexpressing ped/pea-15 show no greater prevalence of spontaneous tumors, but whether insulin-resistance and/or impaired glucose tolerance contribute to the increased susceptibility to skin carcinogenesis cannot be concluded from the present study. Different mechanisms likely play a greater role, however, as TPA-induced upregulation of ped/pea-15 also accompanies skin tumor development in nontransgenic mice featuring normal insulin sensitivity and glucose tolerance. ped/pea-15 performs a broad antiapoptotic action in cultured cells (Condorelli et al., 1999 (Condorelli et al., , 2002 Kitsberg et al., 1999; Hao et al., 2001; Trencia et al., 2004) . At least in part, ped/pea-15 antiapoptotic action is due to inhibition of the induction of the terminal caspase, Caspase-3 (Hao et al., 2001; Condorelli et al., 2002) . In this paper, we show that TPA-induced apoptosis in squamous stratified epithelium in vivo is also significantly inhibited in ped/pea-15 transgenic mice. This decrease is accompanied by reduced activation of Caspase-3 and cleavage of the Caspase-3 substrate PARP in response to TPA. Reduced apoptosis and Caspase-3 activation in response to TPA also occur in the A5 cells, which are derived from DMBA/TPAinduced spindle cell carcinomas and overexpress ped/ pea-15. Consistently, in the normal C5N keratinocytes that express lower levels of endogenous ped/pea-15, transfection of ped/pea-15 cDNA and treatment with the specific Caspase-3 inhibitor Z-DEVD-FMK prevented TPA apoptosis in a nonadditive manner (data not shown). Expression of a specific ped/pea-15 antisense cDNA in the A5 cells simultaneously reduced ped/pea-15 levels and rescued TPA-induced apoptosis and Caspase-3 activation. Importantly, the antisense significantly increased the latency preceding tumor formation upon A5 cell injection in nude mice. The A5 cell growth in semisolid medium was also significantly reduced by decreasing ped/pea-15 expression. Thus, the impaired apotosis determined by inhibition of Caspase-3 activity in ped/pea-15 overexpressing skin cells might affect the malignant progression as well as tumorigenesis.
Previous studies by other investigators and by us have shown that ped/pea-15 may inhibit Caspase-3 function by preventing the activation of Caspase-8 (Condorelli et al., 1999; Kitsberg et al., 1999) as well as by increasing stability of the inhibitor of apoptosis protein XIAP . These events do not account for ped/pea-15 inhibition of Caspase-3 in TPA-treated skin, as ped/pea-15 overexpression does not affect TPA action on either Caspase-8 function or XIAP levels. In certain cell types, block of the JNK and p38 members of the MAPK family also plays an important role in mediating the ped/pea-15 protection from apoptosis (Condorelli et al., 2002) , which may lead to Caspase-3 inhibition (Kamata et al., 2005) . Full antiapoptotic function in these cells requires concomitant ped/pea-15 induction of the ERK1/2 MAPKs and/or ERK1/2 anchoring into the cytoplasm (Formstecher et al., 2001; Condorelli et al., 2002) . Impaired JNK and p38 activation and increased ERK1/2 cytoplasmic activity have also been detected in the skin of Tg ped/pea-15 mice upon exposure to TPA, indicating they may mediate the decreased susceptibility to apoptosis caused by overexpression of ped/pea-15 in these cells. Indeed, same as in other cell types (Condorelli et al., 2002) , in the A5, the rescue of JNK function by overexpression of the upstream kinase MKK6 significantly enhanced the apoptotic response to TPA (data not shown).
Intriguingly, Gaumont-Leclerc et al. (2004) have very recently reported evidence that ped/pea-15 may exert a tumor suppressor function in the IMR90 fibroblasts. It is possible that this function is also exerted in the mouse keratinocyte model. Upon DMBA/TPA exposure of these cells, the antiapoptotic function of ped/pea-15 seems to prevail, however. Consistently, ped/pea-15 overexpression confers raised susceptibility to chemical carcinogenesis in the skin. Thus, different settings may lead ped/pea-15 to have its pro-or antioncogenic functions overriding.
Deregulated apoptosis has been suggested to play an important role in tumorigenesis and malignant progression of transformed cells by contributing the cells with the capability to skip cell death programs, accumulating DNA damage (Debatin and Krammer, 2004) . In certain tumors, these abnormalities may occur because of loss of proapoptotic molecules such as Bax, Apaf-1 or Caspase-8 (Harada and Grant, 2003; Baldi et al., 2004) . In other situations, impaired apoptosis has been associated to increased expression of antiapoptotic molecules of the Bcl-2 family (Harada and Grant, 2003) . In this paper, we have shown that increased expression levels of the antiapoptotic protein ped/pea-15 may also determine susceptibility to skin tumorigenesis and tumor progression by inhibiting Caspase-3-dependent apoptosis in DMBA/TPA-treated mice. Several alterations occurring in these chemically induced mouse skin tumors have also been observed in the homologous cutaneous tumors in humans (Balmain and Harris, 2000) . ped/pea-15 might represent a novel target for cutaneous cancer treatment and prevention.
Materials and methods
Transgenic ped/pea-15 mice
The C57BL/6JxDBA/2J ped/pea-15 transgenic mice were described in Vigliotta et al. (2004) . The animals were maintained in the animal facility at the Dipartimento di Biologia e Patologia Cellulare e Molecolare, Federico II University of Naples. Experiments involving animals were conducted in accordance with accepted standards of animal care and the Italian regulations for the welfare of animals. The study protocol was approved by the Institutional Committee on Animal Care of the University of Naples.
Two-stage skin carcinogenesis
The dorsal skin of 8-week-old mice were shaved, and, 2 days later, a single dose of 50 mg of 7,12-dimethylbenz[a]anthracene (DMBA) in 200 ml of acetone was applied. At 1 week after initiation, the mice were treated with 6.25 mg of 12-Otetradecanoylphorbol-13-acetate (TPA) in 200 ml of acetone twice a week for 15 weeks. The number of papillomas detected by palpation was recorded once a week.
At 1 week after termination of TPA treatment, mice were killed, and skin tissues snap frozen in liquid nitrogen and/or fixed in freshly prepared 4% paraformaldehyde followed by paraffin embedding. Mice were maintained for 35 additional weeks after TPA discontinuation, and tumor progression was investigated. Tumors were scored as papillomas or carcinomas by histological analysis after H&E staining of paraffin sections.
Histology
Tissues were fixed in formalin, dehydrated, blocked in paraffin and sectioned at 6 mm. The tissue sections were stained with hematoxylin and eosin. A total of 76 nonmalignant papillomas and all malignant tumors were examined. Malignant skin tumors were densely cellular spindle cell tumors in the dermis underlying the papilloma, often exhibiting invasion through skeletal muscle and sometimes associated with lymph node metastasis. Premalignant lesions were squamous cells showing atypia (enlarged nuclei, mitotic activity) but not associated with spindle cell proliferation, invasion and metastasis.
Cell culture and growth, transfection and Western blot analysis
The C5N, P1 and A5 cells have been previously described (Portella et al., 1998) and were kindly provided by Dr A Balmain (University of California, San Francisco, Comprehensive Cancer Center, USA). Cells were cultured in DMEM supplemented with 10% foetal calf serum, 10 000 U/ml penicillin, 10 000 mg/ml streptomycin and 2% L-glutamine in a humidified CO 2 incubator as described in Portella et al. (1998) . Transfection of the constitutively active H-Ras61 in C5N cells, tissue collection and Western blots were performed as described in Vigliotta et al. (2004) . The pcDNA-ped/pea-15 antisense construct has been previously described (Hao et al., 2001) . Clones expressing the antisense were selected as in Hao et al. (2001) . Soft agar colony assays were performed according to a previously described technique (Macpherson and Montagnier, 1964) . The antibodies used include ped/pea-15 antibodies (Vigliotta et al., 2004) , phosphoserine 104 ped/pea-15 and phosphoserine 116 ped/pea-15 antibodies , tubulin, caspase-3, XIAP and PARP antibodies (Santa Cruz Biotechnology, CA, USA).
Detection of apoptosis
Animals were subjected to topical applications of acetonedissolved TPA (6.25 mg) or DMBA (50 mg) or acetone alone, as indicated. The animals were killed, skin tissues were removed and then solubilized as in Vigliotta et al. (2004) and processed for the apoptosis assay using the Cell Death Detection ELISA PLUS Kit (Roche Diagnostics GmbH, Mannheim, Germany), according to the manufacturer instructions. For studies in isolated cells, apoptosis was investigated as previously described .
Tumorigenicity assay
Experiments were performed in 6-week old male athymic mice (Charles River, Italy). A5 cells (1 Â 10 6 ), either transfected with the ped/pea-15 antisense cDNA or not, were injected into the right flank of the mice. The animals were monitored for the appearance of tumors and tumor latency was evaluated. The mean tumor latency is the time needed for tumors to reach 10 mm in diameter. All mice were maintained at the animal facility of the Dipartimento di Biologia e Patologia Cellulare e Molecolare of the Federico II University of Naples.
Densitometry and statistical analysis
Densitometric analysis was performed using a Scion Image Analyser. All the data were expressed as mean7s.d. Significance was assessed by Student's t-test for comparison between two means.
